Announcements & Circulars-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

Investors

Information Disclosure

Listing Documents

Financial Reports

Announcements & Circulars

Company Presentation

Corporate Governance

Stock Information

Corporate Communications

Email Subscription

Announcements & Circulars

The announcement begins in December 2019

POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 12, 2026 2026-06-12
VOLUNTARY ANNOUNCEMENT – PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) AS FIRST-LINE TREATMENT FOR HER2+ ADVANCED BREAST CANCER MET PRIMARY ENDPOINT 2026-06-10
Next Day Disclosure Return 2026-06-05
VOLUNTARY ANNOUNCEMENT – INCREASE IN SHAREHOLDING BY EXECUTIVE DIRECTOR AND MANAGEMENT 2026-06-05
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2026 2026-06-04
VOLUNTARY ANNOUNCEMENT – RESEARCH UPDATES OF JSKN016 FOR PRESENTATION AT 2026 ASCO ANNUAL MEETING 2026-06-02
VOLUNTARY ANNOUNCEMENT – RESULTS OF PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) FOR NEOADJUVANT TREATMENT OF BC WERE PRESENTED AT LBA ORAL PRESENTATION SESSION OF 2026 ASCO ANNUAL MEETING 2026-06-01
INSIDE INFORMATION ANNOUNCEMENT – 恩尼妥® (ANBENITAMAB INJECTION) OBTAINED MARKETING APPROVAL FROM THE NMPA 2026-05-29
Next Day Disclosure Return 2026-05-21
FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 12, 2026 2026-05-20